Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Oral TQB3473 Achieves a 56.8% Response Rate in Relapsed/Refractory ITP – JTH
JTH/LinkedIn
Jul 1, 2026, 17:13

Oral TQB3473 Achieves a 56.8% Response Rate in Relapsed/Refractory ITP – JTH

Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Bingjie Ding et al, adding:

”TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study

This phase 1 trial found oral TQB3473 achieved a 56.8% response rate in relapsed/refractory ITP, with 600 mg daily showing the best efficacy-tolerability balance.”

Title: TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study

Authors: Bingjie Ding, Tiejun Gong, Xiangzhou Du, Xiaoming Li, Yinghui Lai, Zhenyu Yan, Rong Fu, Xin Du, Anqi Yang, Jiajia Zhu, Yiran Wang, Hu Zhou

Oral TQB3473 Achieves a 56.8% Response Rate in Relapsed/Refractory ITP - JTH

Stay updated on all scientific advances with Hemostasis Today.

Anqi Yang Bingjie Ding bleeding disorders Health Hematology Hemostasis Hemostasis News Hemostasis Today Hu Zhou Immune thrombocytopenia ITP Jiajia Zhu JTH Medicine Rong Fu Tiejun Gong TKI TQB3473 tyrosine kinase inhibitor Xiangzhou Du Xiaoming Li Xin Du Yinghui Lai Yiran Wang Zhenyu Yan
NewsFeed